Amyloidosis pp 115-121 | Cite as

Isolation and Characterization of Amyloid Enhancing Factor (AEF)

  • M. L. Baltz
  • D. Caspi
  • C. R. K. Hind
  • A. Feinstein
  • M. B. Pepys

Abstract

Injection into mice of extracts of amyloid laden or of normal organs at the same time as a single potent inflammatory stimulus induces the extremely rapid deposition of systemic AA amyloid. This activity has been designated amyloid enhancing factor (AEF) and we report here a preliminary characterization of the material which confirms and extends previous work. AEF activity was extractable from normal murine organs as well as from amyloid laden tissues but in very much smaller amounts, and it was also present in normal or amyloidotic tissues of man, dog, and hamster. AEF extracts are very potent in vivo, as little as 0.002 A280 units being effective. AEF activity was not inhibited by proteinase inhibitors, by nuclease or periodate treatment, by lipid extraction, or by low pH. It was, however, inactivated by proteolytic digestion or by alkaline pH treatment. Gel filtration indicated that the activity resided in a species of apparent molecular weight around 400,000. These findings suggest that AEF depends on a protein component possibly associated with non-protein material. Interestingly preparations of isolated human or murine AA fibrils had the same effect in vivo as AEF.

Keywords

Normal Organ Human Peripheral Blood Mononuclear Cell Peritoneal Exudate Cell Murine Spleen Royal Postgraduate Medical School 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    F. Hardt and P. Ranlov, Int. Rev. Exp. Path., 16: 273 (1976).PubMedGoogle Scholar
  2. 2.
    I. Keizman, A. Rimon, E. Sohar, and J. Gafni, Act. Path. Microbiol. Scand., Section A, 233: 172 (1972).Google Scholar
  3. 3.
    I. Kedar and M. Ravid, Eur. J. Clin. Invest., 10: 63 (1980).PubMedCrossRefGoogle Scholar
  4. 4.
    J. T. Willerson, J. K. Gordon, N. Talal, and W. F. Barth, Arth. Rheum., 12: 232 (1969).CrossRefGoogle Scholar
  5. 5.
    M. A. Axelrad, R. Kisilevsky, J. Willmer, S. J. Chen, and M. Skinner, Lab. Invest., 47: 139 (1982).PubMedGoogle Scholar
  6. 6.
    M. L. Baltz, D. Caspi, I. F. Rowe, C. R. K. Hind, D. J. Evans, and M. B. Pepys, this volume.Google Scholar
  7. 7.
    M. L. Baltz, R. F. Dyck, and M. B. Pepys, Immunology, 41: 59 (1980).PubMedGoogle Scholar
  8. 8.
    A. Boyum, Scand. J. Clin. Lab. Invest., 21, Suppl. 97 (1968).Google Scholar
  9. 9.
    M. Pras, M. Schubert, D. Zucker-Franklin, A. Rimon, and E. C. Franklin, J. Clin. Invest., 47: 924 (1962).Google Scholar
  10. 10.
    M. A. Axelrad and R. Kisilevsky, in: Amyloid and Amyloidosis (G. G. Glenner, P. P. e Costa, and F. Falcao de Freitas, eds.), Excerpta Medica, Amsterdam (1980), p. 527.Google Scholar
  11. 11.
    L. E. Retegui, N. Moguilevsky, C. F. Costracane, and P. L. Masson, Lab. Invest., 50: 323 (1984).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • M. L. Baltz
    • 1
  • D. Caspi
    • 1
  • C. R. K. Hind
    • 1
  • A. Feinstein
    • 2
  • M. B. Pepys
    • 1
  1. 1.MRC Acute Phase Protein Research Group Immunological Medicine Unit Department of MedicineRoyal Postgraduate Medical SchoolUK
  2. 2.AFRC Institute of Animal PhysiologyCambridgeUK

Personalised recommendations